CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 353 enrolled
Drug / intervention
ARO-APOC3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04998201
NCT04998201Phase 2Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia

Arrowhead Pharmaceuticals·interventional·Posted Aug 10, 2021·Updated Apr 14, 2026

In Brief

A Phase 2 clinical trial evaluating ARO-APOC3 and Placebo for Mixed Dyslipidemia. Completed, enrolled 353 participants across 30 sites in 6 countries.

Detailed Summary

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMixed Dyslipidemia
CountriesAustralia, Canada, Hungary, New Zealand, Poland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedAug 10, 2021
Enrollment StartSep 28, 2021
Primary CompletionFeb 10, 2023
Study CompletionAug 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.9 years ago

Interventions

ARO-APOC3drug

ARO-APOC3 Injection

Placebodrug

Sterile Normal Saline (0.9% NaCl)